Lyle Probst, president of PositiveID Corporation (PSID), called in to SmallCapVoice.com, Inc. to discuss all things Firefly Dx. Earlier this year it was announced that PSID had successfully detected the Zika virus on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”). Probst discussed what else Firefly Dx detected in the lab, and how the system test for any pathogen.
PositiveID Corporation™ (OTCQB: PSID) is a life sciences tools and diagnostics company specializing in biological detection and molecular diagnostic systems for America’s homeland defense and the global healthcare market. PositiveID specializes in the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need. PositiveID is also a leader in the mobile technology vehicle market.
This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.